Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavacamten for symptomatic non-obstructive hypertrophic cardiomyopathy
jRCT2051220175Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2023
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing Mavacamten Arm with Placebo Arm (2 arms). Primary endpoints: Change from baseline in Kansas City Cardiomyopathy Questionnaire 23-item Clinical Summary Score and Change from baseline in peak oxygen consumption. Started Mar 2023; status: completed.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on jRCT2051220175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220175.